Drug Profile
DRGT 29
Alternative Names: DRGT-29Latest Information Update: 03 Sep 2020
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 09 Dec 2016 Discontinued - Phase-I for Breast cancer (Metastatic disease) in Hungary (PO)
- 14 Apr 2016 DRGT 29 is available for licensing as of 14 Apr 2016. http://www.drgtco.com